🚨 Clearances, Approvals, Updates, and Recommendations
Quoin Submits First-Ever IND Application for Peeling Skin Syndrome Therapy
New IND pushes QRX003 toward first targeted therapy for peeling skin syndrome, with early pediatric results showing rapid healing and no safety issues.
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
The FDA finalized the addition of bemotrizinol to the OTC sunscreen monograph, approving the broad-spectrum UV filter for use at concentrations up to 6% in adults and children 6 months or older.
Health Canada Grants Priority Review to Birch Triterpenes for EB
The priority review pathway cuts the standard 300-day Canadian review timeline to approximately 180 days, reflecting Health Canada's assessment of serious unmet need in the EB population.
Lebrikizumab Earns FDA Approval for Less Frequent, Every-8-Week Maintenance Dosing in AD
FDA clears lebrikizumab (EBGLYSS) every-8-week maintenance dosing for moderate to severe atopic dermatitis, reducing maintenance injections to as few as 6 per year.
Medicus Pharma Submits Rare Pediatric Disease Designation Request for SkinJect in Gorlin Syndrome
SkinJect demonstrated 64% clinical clearance and 55% complete histological response in a phase 2 study of nodular BCC patients.
Avalo Therapeutics Announces Long-Acting Anti-IL-1β Antibody Program With Potential Applications in HS
Avalo readies long-acting AVTX-010 to target hidradenitis suppurativa, aiming for fewer injections for patients after strong phase 2 abdakibart results.
First HA Injectable for Neck Wrinkles Cleared by FDA
In a pivotal trial, two-thirds of skinvive neck patients maintained clinically significant improvement at six months.
Clear Health Launches Topical Isotretinoin Acne Treatment Without iPLEDGE Requirements
The 3-phase Isoclear regimen pairs topical isotretinoin with clindamycin, tranexamic acid, niacinamide, and copper peptide based on treatment stage.
AbbVie to Acquire Apogee Therapeutics, Expanding AD Pipeline With Zumilokibart
AbbVie’s $10.9B deal adds Apogee’s long-acting IL-13 and TSLP antibodies to its portfolio, aiming for less frequent dosing in atopic dermatitis and asthma.
Ycanth Phase 3 Trial Dosing Begins for Common Warts in US, Japan
Verrica Pharmaceuticals and Japanese partner Torii Pharmaceutical have each dosed a first patient in COVE-3, the second pivotal phase 3 trial testing Ycanth for common warts.
🧬 Big Studies and Big Data
Topical GX-03 Hits 92.6% EASI-50 at Week 4 in Phase 2 AD Interim
Unlike approved AD biologics and JAK inhibitors targeting specific cytokine pathways, GX-03 is designed to modulate inflammatory signaling locally within the skin microenvironment.
Rese-cel Data Support Registrational Strategy Across Dermatomyositis, Systemic Sclerosis, Lupus
Phase 1/2 data from RESET-Myositis, RESET-SSc, and RESET-SLE presented at EULAR 2026 show durable immunomodulator-free responses and a consistent safety profile across indications.
AI Analysis Reveals Menopausal Hair Loss Linked to Systemic Health and Inflammation
AI analysis of 187,016 menopausal women links hair loss severity to thyroid disease, gut symptoms, scalp inflammation, and genetics, supporting broader diagnostic workups beyond hormones.
Semaglutide, Tirzepatide Flag Alopecia Signals in 10-Year FAERS Review
Findings support ongoing pharmacovigilance monitoring of GLP-1 receptor agonists for hair loss, particularly as semaglutide and tirzepatide use continues to expand.
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
More than 35% of zasocitinib-treated patients reached complete skin clearance at week 16, with treatment curve separation emerging as early as week 8.
Quality of Life in CSU Shaped by More Than Skin Symptoms
The review emphasizes that psychological stress can influence inflammatory pathways involved in CSU, potentially worsening disease activity.
đź‘Ą NP/PA Connect
Amy Snow, MSPAS, PA-C, speaks about her collaboration with wellness influencer to fight TikTok skin care myths and share diet-smart acne tips for teens.
Turn Therapeutics is preparing to request an FDA meeting to discuss regulatory strategy and potential pathways toward market following successful Phase 2 completion.
As one of California's first derm PAs, Stern discusses the mentorship-driven private practice model that launched her career and its near-disappearance today.
Career decisions in dermatology are too often driven by emotion rather than data, according to a new practice management column examining common pitfalls in contract evaluation and compensation negotiations.
Lakshi M. Aldredge, MSN, ANP-BC, DCNP, discusses late-breaking data presented at SDNP on novel immune-mediated therapies for atopic dermatitis, alopecia areata, and HS.
Two clinic cases illustrate why dermatologic providers must apply broad general medicine training in every encounter.
Younger patients are embracing preventative injectables and skin care; Shawna Jones, PA-C, urges evidence-based, personalized plans to cut through social-media hype.
Single-Dose IL-2 Fusion Protein Shows Hair Regrowth Signal in Early Trial
HCW9302 selectively expands Treg cells to suppress autoreactive follicular inflammation without broad immunosuppression.
'Invisible Agency': Why Chronic Wound Patients Don't Recognize Their Self-Management Efforts
A new qualitative study finds that patients with hard-to-heal wounds routinely engage in protective and monitoring behaviors at home without recognizing those efforts as meaningful contributions to their own care.
Topical DB-006 Shows Strong Efficacy, Safety in Preclinical AD Model
Derm-Biome Pharmaceuticals reported positive preclinical results for DB-006, a small molecule reducing itch, inflammation, and IgE levels in a model of atopic dermatitis.
đź’ˇ Expert Insights
"Hats On for AK" Campaign Continues to Raise Actinic Keratosis Awareness
Deborah Sarnoff, MD, president of the Skin Cancer Foundation, shares the importance of the "Hats On for AK" social media campaign designed to bring awareness to sun protection and reducing actinic keratosis risk.
The Research Gap Shaping Women's Skin Health Across a Lifetime
Organon's Doral Fredericks, PharmD, MBA, explains why pregnancy and menopause remain chronically understudied in dermatology research and what clinicians are missing as a result.
Dermalogica Enters Medical Aesthetics with FDA-Cleared Microneedling PRO Pen
Michael Gold, MD, explains why the brand's microneedling pen stands out, with customizable depth, speed, and cartridges for rejuvenation and acne-scar treatment credibility.
STAT6 Degradation by KT-621 Correlates With Itch and Lesion Reduction in AD
Jared Gollob, MD, discusses phase 1b biomarker findings for KT-621, a STAT6 degrader in atopic dermatitis, presented at SID 2026.
Plant Adaptogens for Rosacea: Augmenting Prescription Therapy With Skin Care
Zoe Diana Draelos, MD, FAAD, discussed the clinical rationale for incorporating plant adaptogen-based skin care into rosacea management, including how an OTC serum performed alongside prescription therapies.
Why Effective Treatment Must Address Both the Internal and External Scars of Acne
Suneel Chilukuri, MD, explains why acne care requires a holistic approach that treats both visible lesions and the "mental scarring" that affects patient self-confidence.
How a 4-Day Radiation Protocol After Surgery Reduces Keloid Recurrence
William Posten, MD, discusses outcomes, recurrence rates, and the importance of patient adherence in a combined surgical excision and radiation therapy protocol for keloids.
Oral FASN Inhibitor Denifanstat Shows Sebum Reduction, IGA Success in Phase 3 Acne Trial
Julie Harper, MD, discusses phase 3 data for Denifanstat, an oral FASN inhibitor, for acne.
Christopher Bunick, MD, PhD, on Bemotrizinol Approval and Its Role in US Sun Protection
Christopher Bunick, MD, PhD, shares his insights on the FDA approval of bemotrizinol and what the ingredient's properties mean for sun protection and cosmetic elegance.
Clinique's Daily Calm Merges Clinical Efficacy with Color Cosmetics for Sensitive Skin
Michael Ingrassia, PhD, and Ida Wong, MBA, speak about the brand's new line, pairing clinically tested soothing skin care with makeup to calm reactive skin and strengthen the barrier.
Medicus Pharma Targets Gorlin Syndrome and BCC Backlog with Novel Immuno-Oncology Patch
Microneedle SkinJect patch aims to clear basal cell carcinoma without surgery, showing phase 2 promise and expanding to Gorlin syndrome trials.
Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.
